Singapore-headquartered biotech company Lion TCR has raised $40 million in a Series B2 funding round led by state investor Guangzhou Industrial Investment and Capital Operation Holding Group, according to a company statement.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
